ABSTRACT
BACKGROUND: To evaluate the use of cellular immunity parameters as predictors of therapy response. METHODS: Circulating lymphocytes were measued by flow cytometry in 94 nasopharyngeal carcinoma (NPC) patients following radiochemotherapy. RESULTS: Significantly decreased percentage of CD3(+), CD4(+), and CD8(+) lymphocytes, significantly increased proportion of CD44(+), CD25(+), NK lymphocytes, and an increased CD4(+)/CD8(+) ratio were indicated in NPC patients as compared with healthy controls. Circulating CD44(+) lymphocytes in both the N2/N3 and III/IV groups were significantly increased as compared to the N0/N1 and I/II groups, respectively (P<0.05). A significant decrease in CD19(+) lymphocytes was observed in the III/IV group as compared with the I/II group (P<0.05). After radiochemotherapy, NPC patients had significantly (P<0.05) decreased percentages of CD4(+), CD44(+), and CD19(+) lymphocytes and a decreased CD4(+)/CD8(+) ratio, whereas the mean percentages of CD8(+) and NK lymphocytes were significantly (P<0.05) increased. However, compared with the pre-radiochemotherapy values, no significant (P>0.05) changes in CD3(+) or CD25(+) lymphocytes were observed in the NPC-treated group. Follow-up analysis indicated significantly lower DFS for patients with high CD44(+) lymphocytes compared to those with low CD44(+) lymphocytes after radiochemotherapy. CONCLUSION: Circulating CD44(+) lymphocytes seems to be a promising criterion to predict survival in NPC patients undergoing radiochemotherapy.
Subject(s)
Hyaluronan Receptors/blood , Lymphocytes/immunology , Nasopharyngeal Neoplasms/blood , Case-Control Studies , Combined Modality Therapy , Flow Cytometry , Humans , Immunophenotyping , Nasopharyngeal Neoplasms/drug therapy , Nasopharyngeal Neoplasms/immunology , Nasopharyngeal Neoplasms/radiotherapy , Survival AnalysisSubject(s)
Carcinoma, Squamous Cell/immunology , Cytokines/blood , Esophageal Neoplasms/immunology , Th1 Cells/immunology , Th2 Cells/immunology , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/pathology , Esophageal Neoplasms/pathology , Female , Humans , Interferon-gamma/blood , Interleukin-10/blood , Interleukin-12/blood , Interleukin-4/blood , Interleukin-5/blood , Lymphatic Metastasis , Male , Middle Aged , Tumor Necrosis Factor-alpha/bloodABSTRACT
OBJECTIVE: To establish human multidrug-resistant lung carcinoma cell line (D6/MVP) with its characteristics studied. METHODS: Intermittent administration of high-dose MMC, VDS and DDP (MVP) was used to induce human lung carcinoma cell line (D6) to a multidrug-resistant variety (D6/MVP). MTT assay was used to study the multidrug resistance of D6/MVP to multianticarcinogen. Flow cytometry was used to study the cell cycle distribution and the expression of P-gp, multidrug resistance-associated protein (MRP) and GSH/GST. RESULTS: 1. D6/MVP was resistant to many anti-tumor agents, with the IC(50) 13.3 times higher and the drug resistance 2 - 6 times higher than D6, 2. The multiplication time of D6/MVP was prolonged and the cell number of S-phase decreased while that of G1- and G(2)-phase increased and 3. The expression of P-gp and MRP was enhanced significantly (96.2% vs 51.7%), but the expression of GSH/GST kept stable. CONCLUSION: D6/MVP is a multidrug-resistant cell line possessing the basic characteristics of drug-resistance.
